Table 3.

Patients (%) with treatment-emergent adverse events, regardless of causality, that occurred in ≥30% of patients

TEAE	All patients	EKB25, CAPE750	EKB50, CAPE750	EKB50, CAPE1000	EKB75, CAPE1000
	N = 37	n = 6	n = 7	n = 20	n = 4
Diarrhea
Grade 1–4	32 (86)	5	5	18 (90)	4
Grade 3–4	8 (22)	1	5	1 (5)	1
Nausea
Grade 1–4	27 (73)	6	4	15 (75)	2
Grade 3–4	2 (5)	2	0	0	0
Asthenia
Grade 1–4	25 (68)	5	3	14 (70)	3
Grade 3–4	1 (3)	0	1	0	0
Anorexia
Grade 1–4	22 (59)	4	2	13 (65)	3
Grade 3–4	1 (3)	1	0	0	0
Abdominal pain
Grade 1–4	21 (57)	5	4	10 (50)	2
Grade 3–4	3 (8)	2	1	0	0
Rash
Grade 1–2	18 (49)	3	4	10 (50)	1
Vomiting
Grade 1–4	17 (46)	2	2	12 (60)	1
Grade 3–4	3 (8)	2	1	0	0
Skin disorder
Grade 1–4	16 (43)	2	3	10 (50)	1
Grade 3–4	1	1	0	0	0
Stomatitis
Grade 1–2	13 (35)	2	1	10 (50)	0
Fever
Grade 1–4	11 (30)	2	0	8 (40)	1
Grade 3–4	1 (3)	0	1	0	0
Pain
Grade 1–4	11 (30)	2	3	5 (25)	1

Abbreviations: EKB25, CAPE750, EKB-569 25 mg and capecitabine 750 mg/m²; EKB50, CAPE750, EKB-569 50 mg and capecitabine 750 mg/m²; EKB50, CAPE1000, EKB-569 50 mg and capecitabine 1,000 mg/m²; EKB75, CAPE1000, EKB-569 75 mg and capecitabine 1,000 mg/m²; TEAE, treatment-emergent adverse event.